Abstract

Only a few studies have explored the benefit of deprescribing in people living with HIV (PLWH), focusing on the discontinuation of non-antiretrovirals (non-ARVs) used for HIV-associated comorbidities (co-medications), or the management of drug–drug interactions (DDIs) between ARVs or between ARVs and co-medications. The availability of modern single-tablet regimens, two-drug regimens and long-acting therapy opens a discussion regarding ARV deprescribing strategies. The objective of this article is to discuss ARV deprescribing strategies in the context of medication-related burden and patients’ lived experience with medicine (PLEM) and to suggest indications for whom, when, how and why to consider these ARV options in PLWH. A PLEM construct helps to better interpret these strategies and provides a patient-centred precision-medicine approach. There are several safe and virologically effective ARV deprescribing strategies, but the ultimate benefits of these interventions still need to be further explored in terms of the overall health and quality of life of patients.

中文翻译：

---

以患者为中心的方法，在艾滋病毒感染者中停用抗逆转录病毒疗法。

摘要

只有少数研究探讨了在艾滋病毒感染者中停用处方药的益处，重点在于停用用于与艾滋病毒相关的合并症（联合用药）或药物管理的非抗逆转录病毒药物（非ARV） ARV之间或ARV与联合药物之间的药物相互作用（DDI）。现代单片治疗方案，两药治疗方案和长效疗法的可用性开启了有关抗逆转录病毒药物处方策略的讨论。本文的目的是在与药物相关的负担和患者的医学生活经验（PLEM）的背景下讨论ARV停用策略，并建议在PLWH中为谁，何时，如何以及为什么考虑这些ARV选项的适应症。PLEM构建有助于更好地解释这些策略，并提供以患者为中心的精确医学方法。